eyeforpharma is now Reuters Events - LEARN MORE
New columnist, Jeffrey Frick shares insights on the Chinese healthcare market.
The clinical trial process is a costly and integral part of bringing a drug to market, but does it have to be carried out the way it is currently? Is there a better way?
by Jeff Elton
Investment in real-world data, advanced analytics, and value-delivering services by life sciences companies is growing rapidly, particularly in the US and Europe. These companies are changing their commercial operating models as they attempt to improve patient and health system value outcomes.
by Marc Yates
China’s population has aged much faster than other populations, and this rapid aging poses challenges to healthcare, among which the most common are a surging healthcare expenditure and a rising difficulty in managing the 'iron triangle'.
We reflect on the past 12 months from the patient perspective – it has been a phenomenal year of successes, stories and surprises.
by David Laws
Customer Centricity, Communities of Practice, Big Data, Patient Centricity (probably), The Digital Organization and many more business model innovations have failed to take serious hold in pharma over the years.
With patient centricity firmly on the agenda, what is true patient centricity and how can we translate the intent to align more with action? I interviewed executives at Novo Nordisk and Sanofi to highlight the three key things to consider when seeking to be patient centric.
by Marc Yates
In 2009 the Brazilian government passed the Generics Drugs Act; one of numerous initiatives intended to reduce spend on originator branded drugs, whilst boosting generic drug prescription and supporting the domestic drug industry.
The healthcare delivery market is undergoing dramatic change, adapting to survive in a much tougher business climate we call Healthcare 2.0. This should prompt pharma organizations to reevaluate the assumptions on which they’ve built their commercial model, or they risk falling behind the curve.
Dr Andree Bates looks at the impact of precision medicine on pharma and the change in mindset necessary to fit this new reality.
There is an epidemic of sticking roughly to the previous year's plan and budget. This may be useful if that approach is getting you to be the top brand, but if your results are not radically improving you need to examine both your strategy and budget allocation carefully.
by Paul Simms
Rice Powell, Chairman of the Board and CEO for Fresenius Medical Care, speaks to Paul Simms, eyeforpharma Chairman. Fresenius Medical Care is a company well-known for being the first to successfully pioneer a vertically-intergrated, service-oriented model within healthcare.
by Jeff Elton
As we enter into the "Value Era", innovating and delivering value is about understanding critical connections, gaps, and potential solutions or alternatives to each. Jeff Elton discusses the exciting emergence of a truly global health services solutions market.
Although the exchanges have the potential to expand the market for some therapeutic areas, the way in which they are designed will likely have an impact on consumer purchasing behavior. Manufacturers need to understand how consumers are responding and what these changes mean for their business.